TY - JOUR T1 - Spectrum of innate and adaptive immune response to SARS-CoV-2 infection across asymptomatic, mild and severe cases – a longitudinal cohort study JF - medRxiv DO - 10.1101/2020.06.22.20137141 SP - 2020.06.22.20137141 AU - Rita Carsetti AU - Salvatore Zaffina AU - Eva Piano Mortari AU - Sara Terreri AU - Francesco Corrente AU - Claudia Capponi AU - Patrizia Palomba AU - Mattia Mirabella AU - Simona Cascioli AU - Paolo Palange AU - Ilaria Cuccaro AU - Cinzia Milito AU - Alimuddin Zumla AU - Markus Maeurer AU - Vincenzo Camisa AU - Maria Rosaria Vinci AU - Annapaola Santoro AU - Eleonora Cimini AU - Luisa Marchioni AU - Emanuele Nicastri AU - Fabrizio Palmieri AU - Chiara Agrati AU - Giuseppe Ippolito AU - Ottavia Porzio AU - Carlo Concato AU - Andrea Onetti Muda AU - Massimiliano Raponi AU - Concetta Quintarelli AU - Isabella Quinti AU - Franco Locatelli Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/23/2020.06.22.20137141.abstract N2 - Background SARS-CoV-2 is a novel coronavirus, not encountered before by humans. The wide spectrum of clinical expression of SARS-CoV-2 illness suggests that individual immune responses to SARS-CoV-2 play a crucial role in determining the clinical course after first infection.Immunological studies have focussed on patients with moderate to severe disease, demonstrating excessive inflammation in tissues and organ damage.We have studied the individual response to SARS-CoV-2 of asympromatic, mild and severe COVID-19 patients in order to investigate the role of innnate and adaptive immunity in determining the clinical course after first infection.Methods To understand the basis of the protective immune response in COVID-19, we performed a longitudinal follow-up analysis of innate and adaptive immunity in 64 adults with a spectrum of clinical presentations: (28 healthy SARS-CoV-2-negative contacts of COVID-19 cases; 20 asymptomatic SARS-CoV-2-infected cases; 8 patients with mild COVID-19 disease and 8 cases of severe COVID-19 disease).Results Our data show that high frequency of NK cells and early and transient increase of specific IgA and, to a lower extent, IgG are associated to asymptomatic SARS-CoV-2 infection. By contrast, monocyte expansion and high and persistent levels of IgA and IgG, produced relatively late in the course of the infection, characterize severe disease. Modest increase of monocytes and rapidly declining antibodies are detected in mild COVID-19.Conclusions The importance of innate NK cells and the short-lived antibody response of asymptomatic individuals and patients with mild disease suggest that only severe COVID-19 may result in protective memory established by the adaptive immune response.Summary The ratio between monocytes and NK may represent a prognostic marker of disease development in COVID-19. Individuals with asymptomatic SARS-CoV2 infection have a high frequency of NK cells associated to a transient IgA response to the infectionCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was founded by the RF2013-02358960 grant from the Italian Ministry of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Medical Research and Ethics Committee at Sapienza, University of Rome. The study was performed in accordance with the Good Clinical Practice guidelines, the International Conference on Harmonization guidelines, and the most recent version of the Declaration of HelsinkiAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesno datasets or other repositoriesSARS-CoV-2Severe Adult Respiratory Syndrome-Coronavirus-2COVID-19Coronavirus Disease 2019ACE2Angiotensin Converting Enzyme-2MBCsmemory B cellsMLRMonocyte-Lymphocyte ratioNLRNeutrophil-Lymphocyte ratioMNKRMonocyte-NK ratioIFN-γinterferon-gammaHLHHemophagocytic LymphohistiocytosisTGF-betatransforming growth factor-beta ER -